28-01-2026, 12:35

Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial

Notified -
Globe Newswire28-01-2026, 12:35
1-03-2023, 21:29

ZyVersa Therapeutics to Participate in a Fireside Chat at

CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux
Globe Newswire1-03-2023, 21:29